RxDoctor Payments Data

Rolf Panke, DO

Family Medicine · Davenport, WANPI 1396782272

Payments from drug & device makers

$2,096in general payments, 2019–2025

Across 209 payments — averaging $10.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$680
  • Pfizer$629
  • Novo Nordisk$203
  • Amgen$202
  • AstraZeneca$129
  • Astellas Pharma US Inc$51
  • plus $201 from 8 others

What the payments were for

  • Food & beverage$2,00396%
  • Education$934%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,096 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$19,167
Medicare patients
71
Services billed
186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban248$204,614
OzempicSemaglutide143$155,887
JardianceEmpagliflozin45$55,656
JanuviaSitagliptin Phosphate31$30,658
EliquisApixaban38$25,606
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$17,413
Breo ElliptaFluticasone/Vilanterol31$12,820
InvokanaCanagliflozin15$12,638
OxycontinOxycodone Hcl12$12,417
Invokamet XrCanagliflozin/Metformin Hcl12$10,389
LinzessLinaclotide17$9,055
Spiriva HandihalerTiotropium Bromide15$8,926
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen384$7,371
Fluticasone-SalmeterolFluticasone Propion/Salmeterol54$6,321
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$6,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto, Invokana$680$217,252263 claims
Novo NordiskOzempic$203$155,887143 claims
Boehringer IngelheimJardiance, Stiolto Respimat$29$61,71458 claims
MerckJanuvia$13$30,65831 claims
PfizerEliquis$629$25,60638 claims
AbbVieLinzess$21$9,05517 claims
AstraZenecaPulmicort Flexhaler$129$2,79511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Davenport

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →